Join the members of our Sarcoma Disease Site Work Group for an insightful journal club where important articles will be reviewed. This virtual journal club will focus on a series of phase III trial data on the use of second line treatments after imatinib progression in patients with advanced GIST, as well as outcomes after 3 versus 6 years of imatinib treatment for patients with high-risk GIST. Review of the articles ahead of time is recommended to get the most out of this session.

Faculty for this event are listed below:

Konstantinos Chouliaras, MD (Planner/Moderator)
MD Anderson Cancer Center 

Jason Sicklick, MD (Faculty)
University of California, San Diego

Neeta Somaiah, MD (Faculty)
MD Anderson Cancer Center

Breelyn A. Wilky, MD (Faculty)
University of Colorado, Anschutz Medical Campus

This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with sarcoma cancer.

At the conclusion of this activity, participants should gain strategies to:

• Better counsel and treat patients after progression/intolerance to Imatinib, using Ripretinib or Sunitinib.
• Educate and counsel patients on the role of continuing Imatinib beyond 3 years.
• Better understand recent phase III trial data on the development of Imatinib resistance after treatment interruptions.

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Surgical Oncology designates this internet live course for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity consists of educational content and an evaluation. Learners must view the activity content and complete the post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.

The estimated time to complete this entire activity is 1 hour.

Release Date

           December 5, 2024

CME Expiration Date

           December 5, 2025

As required by the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all planners, reviewers, presenters, instructors, moderators, authors, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company that have occurred within the past 24 months. Ineligible companies are those that cannot be accredited in the ACCME System and whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

As the accredited provider, SSO is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into the education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

All identified conflicts of interest must be mitigated, and the educational content vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.

All identified conflicts of interests have been mitigated.

Faculty
Konstantinos Chouliaras, MD (Planner/Moderator), has disclosed no financial relationships.

Jason Sicklick, MD (Faculty), has disclosed no financial relationships.

Neeta Somaiah, MD (Faculty), has disclosed the following financial relationships: Deciphera (Advisor and Contracted Research), Ipsen (Advisor), Boehringer Ingelheim (Advisor and Contracted Research), Bayer (Advisor and Contracted Research), Replimmune (Advisor), Alexion Advisory Board (Advisor), IDRX (Contracted Research), Cogent (Contracted Research) and Ascentage (Contracted Research).

Breelyn Wilky, MD (Faculty), has disclosed no financial relationships.

Planners, Reviewers, and Staff
Emily Keung, MD, CME Committee Reviewer, has disclosed no financial relationships.

Devin Winkler, Society of Surgical Oncology, has disclosed no financial relationships.

The primary purpose of the Society of Surgical Oncology's internet live course is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site: https://www.surgonc.org/about-sso/privacy-policy/ .

System requirements for this activity can be found by clicking the Help button. For technical support, please contact us at expertED@surgonc.org